Gilead Sciences Q3 FY25: where the revenue came from and where it went
The whole income statement of Gilead Sciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 7, 2025
Revenue$7.77B
+3% year over year
Gross profit$6.20B
80% margin
Operating profit$3.33B
43% margin
Net profit$3.05B
39% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 7.77 | 100% | +3% |
| Biktarvy | 3.69 | 47% | |
| Other revenue | 1.41 | 18% | |
| Total oncology | 0.79 | 10% | |
| Total cell therapy | 0.43 | 6% | |
| Royalty, contract & other | 0.42 | 5% | |
| Genvoya | 0.38 | 5% | |
| Yescarta | 0.35 | 5% | |
| Sofosbuvir/Velpatasvir | 0.31 | 4% | |
| Cost of revenue | −1.57 | 20% | |
| Gross profit | 6.20 | 80% margin | +1pp |
| SG&A | −1.36 | 17% | −2pp |
| Other | −1.52 | 20% | +0pp |
| Operating profit | 3.33 | 43% margin | +31pp |
| Other income, net | 0.31 | ||
| Tax | −0.59 | ||
| Net profit | 3.05 | 39% margin | +23pp |
347 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest